New cancer drug LUNA18 tested in early human trial
NCT ID NCT05012618
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial tested a new drug called LUNA18, taken as a capsule, alone or with another cancer drug (cetuximab), in 128 adults with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check safety, find the right dose, and see how the drug moves through the body. The trial was terminated early, so its full results are not available.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
LUNA18 (a drug taken as a capsule) and cetuximab (given as an IV infusion)
What this could lead to
If successful, this could point toward a new treatment option for people with advanced solid tumors that have not responded to standard therapies.
What could go wrong
This is a very early Phase 1 trial focused on safety and dosing, not on proving effectiveness. The trial was terminated, so results may not be available. Side effects are unknown and could be significant.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED OR METASTATIC SOLID TUMORS are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Abramson Cancer Center at Pennsylvania Hospital
Philadelphia, Pennsylvania, 19106, United States
-
Aichi Cancer Center
Nagoya, Aichi-ken, 464-8681, Japan
-
Barbara Ann Karmanos Cancer Institute
Detroit, Michigan, 48201, United States
-
Beth Israel Deaconess
Boston, Massachusetts, 02215, United States
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Icahn School of Medicine at Mount Sinai
New York, New York, 10029, United States
-
MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
NEXT Oncology
Austin, Texas, 78758, United States
-
NEXT Virginia
Fairfax, Virginia, 22031, United States
-
National Cancer Center Hospital
Chuo-Ku, Tokyo, 104-0045, Japan
-
National Cancer Center Hospital East
Kashiwa, Chiba, 277-8577, Japan
-
National Hospital Organization Kyushu Cancer Center
Fukuoka, 811-1395, Japan
-
Osaka International Cancer Institute
Osaka, 541-8567, Japan
-
Renown Regional Medical Center
Reno, Nevada, 89502, United States
-
Rhode Island Hospital-Comprehensive Cancer Center
Providence, Rhode Island, 02903, United States
-
Shizuoka Cancer Center
Nakatogari, Shizuoka, 411-0934, Japan
-
South Texas Accelerated Research Therapeutics (START) Midwest
Grand Rapids, Michigan, 49546, United States
-
The Cancer Institute Hospital of JFCR
Koto-ku, Tokyo, 135-8550, Japan
-
University of California - Davis
Davis, California, 95616, United States
-
University of Wisconsin - Carbone Cancer Center
Madison, Wisconsin, 53792, United States